Global Spinal and Bulbar Muscular Atrophy Treatment Market Research Report 2023

Spinal and Bulbar Muscular Atrophy Treatment Market

SBMA, mainly manifested as systemic muscle atrophy, paralysis and systemic muscle bundle tremor, patients with systemic muscle weakness, especially the weakness of the two lower limbs to walk, tongue muscle atrophy is usually one of the main symptoms.

The global Spinal and Bulbar Muscular Atrophy Treatment market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

North American market for Spinal and Bulbar Muscular Atrophy Treatment is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

Asia-Pacific market for Spinal and Bulbar Muscular Atrophy Treatment is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

The global market for Spinal and Bulbar Muscular Atrophy Treatment in Hospitals is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

The key global companies of Spinal and Bulbar Muscular Atrophy Treatment include AbbVie, Pfizer, GlaxoSmithKline, Johnson & Johnson, Century Pharmaceuticals, Astellas Pharma, Sanofi and Boehringer Ingelheim International, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Spinal and Bulbar Muscular Atrophy Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Spinal and Bulbar Muscular Atrophy Treatment.

The Spinal and Bulbar Muscular Atrophy Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Spinal and Bulbar Muscular Atrophy Treatment market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Spinal and Bulbar Muscular Atrophy Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.

Scope of Spinal and Bulbar Muscular Atrophy Treatment Market Report

Core Chapters

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Spinal and Bulbar Muscular Atrophy Treatment Market Size Growth Rate by Type: 2018 VS 2022 VS 2029

1.2.2 5α-Reductase Inhibitors

1.2.3 Gonadotropin-releasing Hormone Agonists

1.3 Market by Application

1.3.1 Global Spinal and Bulbar Muscular Atrophy Treatment Market Growth by Application: 2018 VS 2022 VS 2029

1.3.2 Hospitals

1.3.3 Orthopedic Clinics

1.3.4 Ambulatory Surgical Centers

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2.1 Global Spinal and Bulbar Muscular Atrophy Treatment Market Perspective (2018-2029)

2.2 Spinal and Bulbar Muscular Atrophy Treatment Growth Trends by Region

2.2.1 Global Spinal and Bulbar Muscular Atrophy Treatment Market Size by Region: 2018 VS 2022 VS 2029

2.2.2 Spinal and Bulbar Muscular Atrophy Treatment Historic Market Size by Region (2018-2023)

2.2.3 Spinal and Bulbar Muscular Atrophy Treatment Forecasted Market Size by Region (2024-2029)

2.3 Spinal and Bulbar Muscular Atrophy Treatment Market Dynamics

2.3.1 Spinal and Bulbar Muscular Atrophy Treatment Industry Trends

2.3.2 Spinal and Bulbar Muscular Atrophy Treatment Market Drivers

2.3.3 Spinal and Bulbar Muscular Atrophy Treatment Market Challenges

2.3.4 Spinal and Bulbar Muscular Atrophy Treatment Market Restraints

3.1 Global Top Spinal and Bulbar Muscular Atrophy Treatment Players by Revenue

3.1.1 Global Top Spinal and Bulbar Muscular Atrophy Treatment Players by Revenue (2018-2023)

3.1.2 Global Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Share by Players (2018-2023)

3.2 Global Spinal and Bulbar Muscular Atrophy Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Spinal and Bulbar Muscular Atrophy Treatment Revenue

3.4 Global Spinal and Bulbar Muscular Atrophy Treatment Market Concentration Ratio

3.4.1 Global Spinal and Bulbar Muscular Atrophy Treatment Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Spinal and Bulbar Muscular Atrophy Treatment Revenue in 2022

3.5 Spinal and Bulbar Muscular Atrophy Treatment Key Players Head office and Area Served

3.6 Key Players Spinal and Bulbar Muscular Atrophy Treatment Product Solution and Service

3.7 Date of Enter into Spinal and Bulbar Muscular Atrophy Treatment Market

3.8 Mergers & Acquisitions, Expansion Plans

4.1 Global Spinal and Bulbar Muscular Atrophy Treatment Historic Market Size by Type (2018-2023)

4.2 Global Spinal and Bulbar Muscular Atrophy Treatment Forecasted Market Size by Type (2024-2029)

5.1 Global Spinal and Bulbar Muscular Atrophy Treatment Historic Market Size by Application (2018-2023)

5.2 Global Spinal and Bulbar Muscular Atrophy Treatment Forecasted Market Size by Application (2024-2029)

6.1 North America Spinal and Bulbar Muscular Atrophy Treatment Market Size (2018-2029)

6.2 North America Spinal and Bulbar Muscular Atrophy Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029

6.3 North America Spinal and Bulbar Muscular Atrophy Treatment Market Size by Country (2018-2023)

6.4 North America Spinal and Bulbar Muscular Atrophy Treatment Market Size by Country (2024-2029)

6.5 United States

6.6 Canada

7.1 Europe Spinal and Bulbar Muscular Atrophy Treatment Market Size (2018-2029)

7.2 Europe Spinal and Bulbar Muscular Atrophy Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029

7.3 Europe Spinal and Bulbar Muscular Atrophy Treatment Market Size by Country (2018-2023)

7.4 Europe Spinal and Bulbar Muscular Atrophy Treatment Market Size by Country (2024-2029)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8.1 Asia-Pacific Spinal and Bulbar Muscular Atrophy Treatment Market Size (2018-2029)

8.2 Asia-Pacific Spinal and Bulbar Muscular Atrophy Treatment Market Growth Rate by Region: 2018 VS 2022 VS 2029

8.3 Asia-Pacific Spinal and Bulbar Muscular Atrophy Treatment Market Size by Region (2018-2023)

8.4 Asia-Pacific Spinal and Bulbar Muscular Atrophy Treatment Market Size by Region (2024-2029)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9.1 Latin America Spinal and Bulbar Muscular Atrophy Treatment Market Size (2018-2029)

9.2 Latin America Spinal and Bulbar Muscular Atrophy Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029

9.3 Latin America Spinal and Bulbar Muscular Atrophy Treatment Market Size by Country (2018-2023)

9.4 Latin America Spinal and Bulbar Muscular Atrophy Treatment Market Size by Country (2024-2029)

9.5 Mexico

9.6 Brazil

10.1 Middle East & Africa Spinal and Bulbar Muscular Atrophy Treatment Market Size (2018-2029)

10.2 Middle East & Africa Spinal and Bulbar Muscular Atrophy Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029

10.3 Middle East & Africa Spinal and Bulbar Muscular Atrophy Treatment Market Size by Country (2018-2023)

10.4 Middle East & Africa Spinal and Bulbar Muscular Atrophy Treatment Market Size by Country (2024-2029)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11.1 AbbVie

11.1.1 AbbVie Company Detail

11.1.2 AbbVie Business Overview

11.1.3 AbbVie Spinal and Bulbar Muscular Atrophy Treatment Introduction

11.1.4 AbbVie Revenue in Spinal and Bulbar Muscular Atrophy Treatment Business (2018-2023)

11.1.5 AbbVie Recent Development

11.2 Pfizer

11.2.1 Pfizer Company Detail

11.2.2 Pfizer Business Overview

11.2.3 Pfizer Spinal and Bulbar Muscular Atrophy Treatment Introduction

11.2.4 Pfizer Revenue in Spinal and Bulbar Muscular Atrophy Treatment Business (2018-2023)

11.2.5 Pfizer Recent Development

11.3 GlaxoSmithKline

11.3.1 GlaxoSmithKline Company Detail

11.3.2 GlaxoSmithKline Business Overview

11.3.3 GlaxoSmithKline Spinal and Bulbar Muscular Atrophy Treatment Introduction

11.3.4 GlaxoSmithKline Revenue in Spinal and Bulbar Muscular Atrophy Treatment Business (2018-2023)

11.3.5 GlaxoSmithKline Recent Development

11.4 Johnson & Johnson

11.4.1 Johnson & Johnson Company Detail

11.4.2 Johnson & Johnson Business Overview

11.4.3 Johnson & Johnson Spinal and Bulbar Muscular Atrophy Treatment Introduction

11.4.4 Johnson & Johnson Revenue in Spinal and Bulbar Muscular Atrophy Treatment Business (2018-2023)

11.4.5 Johnson & Johnson Recent Development

11.5 Century Pharmaceuticals

11.5.1 Century Pharmaceuticals Company Detail

11.5.2 Century Pharmaceuticals Business Overview

11.5.3 Century Pharmaceuticals Spinal and Bulbar Muscular Atrophy Treatment Introduction

11.5.4 Century Pharmaceuticals Revenue in Spinal and Bulbar Muscular Atrophy Treatment Business (2018-2023)

11.5.5 Century Pharmaceuticals Recent Development

11.6 Astellas Pharma

11.6.1 Astellas Pharma Company Detail

11.6.2 Astellas Pharma Business Overview

11.6.3 Astellas Pharma Spinal and Bulbar Muscular Atrophy Treatment Introduction

11.6.4 Astellas Pharma Revenue in Spinal and Bulbar Muscular Atrophy Treatment Business (2018-2023)

11.6.5 Astellas Pharma Recent Development

11.7 Sanofi

11.7.1 Sanofi Company Detail

11.7.2 Sanofi Business Overview

11.7.3 Sanofi Spinal and Bulbar Muscular Atrophy Treatment Introduction

11.7.4 Sanofi Revenue in Spinal and Bulbar Muscular Atrophy Treatment Business (2018-2023)

11.7.5 Sanofi Recent Development

11.8 Boehringer Ingelheim International

11.8.1 Boehringer Ingelheim International Company Detail

11.8.2 Boehringer Ingelheim International Business Overview

11.8.3 Boehringer Ingelheim International Spinal and Bulbar Muscular Atrophy Treatment Introduction

11.8.4 Boehringer Ingelheim International Revenue in Spinal and Bulbar Muscular Atrophy Treatment Business (2018-2023)

11.8.5 Boehringer Ingelheim International Recent Development

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

List of Tables

    Table 1. Global Spinal and Bulbar Muscular Atrophy Treatment Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029

    Table 2. Key Players of 5α-Reductase Inhibitors

    Table 3. Key Players of Gonadotropin-releasing Hormone Agonists

    Table 4. Global Spinal and Bulbar Muscular Atrophy Treatment Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029

    Table 5. Global Spinal and Bulbar Muscular Atrophy Treatment Market Size by Region (US$ Million): 2018 VS 2022 VS 2029

    Table 6. Global Spinal and Bulbar Muscular Atrophy Treatment Market Size by Region (2018-2023) & (US$ Million)

    Table 7. Global Spinal and Bulbar Muscular Atrophy Treatment Market Share by Region (2018-2023)

    Table 8. Global Spinal and Bulbar Muscular Atrophy Treatment Forecasted Market Size by Region (2024-2029) & (US$ Million)

    Table 9. Global Spinal and Bulbar Muscular Atrophy Treatment Market Share by Region (2024-2029)

    Table 10. Spinal and Bulbar Muscular Atrophy Treatment Market Trends

    Table 11. Spinal and Bulbar Muscular Atrophy Treatment Market Drivers

    Table 12. Spinal and Bulbar Muscular Atrophy Treatment Market Challenges

    Table 13. Spinal and Bulbar Muscular Atrophy Treatment Market Restraints

    Table 14. Global Spinal and Bulbar Muscular Atrophy Treatment Revenue by Players (2018-2023) & (US$ Million)

    Table 15. Global Spinal and Bulbar Muscular Atrophy Treatment Market Share by Players (2018-2023)

    Table 16. Global Top Spinal and Bulbar Muscular Atrophy Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Spinal and Bulbar Muscular Atrophy Treatment as of 2022)

    Table 17. Ranking of Global Top Spinal and Bulbar Muscular Atrophy Treatment Companies by Revenue (US$ Million) in 2022

    Table 18. Global 5 Largest Players Market Share by Spinal and Bulbar Muscular Atrophy Treatment Revenue (CR5 and HHI) & (2018-2023)

    Table 19. Key Players Headquarters and Area Served

    Table 20. Key Players Spinal and Bulbar Muscular Atrophy Treatment Product Solution and Service

    Table 21. Date of Enter into Spinal and Bulbar Muscular Atrophy Treatment Market

    Table 22. Mergers & Acquisitions, Expansion Plans

    Table 23. Global Spinal and Bulbar Muscular Atrophy Treatment Market Size by Type (2018-2023) & (US$ Million)

    Table 24. Global Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Share by Type (2018-2023)

    Table 25. Global Spinal and Bulbar Muscular Atrophy Treatment Forecasted Market Size by Type (2024-2029) & (US$ Million)

    Table 26. Global Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Share by Type (2024-2029)

    Table 27. Global Spinal and Bulbar Muscular Atrophy Treatment Market Size by Application (2018-2023) & (US$ Million)

    Table 28. Global Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Share by Application (2018-2023)

    Table 29. Global Spinal and Bulbar Muscular Atrophy Treatment Forecasted Market Size by Application (2024-2029) & (US$ Million)

    Table 30. Global Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Share by Application (2024-2029)

    Table 31. North America Spinal and Bulbar Muscular Atrophy Treatment Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 32. North America Spinal and Bulbar Muscular Atrophy Treatment Market Size by Country (2018-2023) & (US$ Million)

    Table 33. North America Spinal and Bulbar Muscular Atrophy Treatment Market Size by Country (2024-2029) & (US$ Million)

    Table 34. Europe Spinal and Bulbar Muscular Atrophy Treatment Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 35. Europe Spinal and Bulbar Muscular Atrophy Treatment Market Size by Country (2018-2023) & (US$ Million)

    Table 36. Europe Spinal and Bulbar Muscular Atrophy Treatment Market Size by Country (2024-2029) & (US$ Million)

    Table 37. Asia-Pacific Spinal and Bulbar Muscular Atrophy Treatment Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029

    Table 38. Asia-Pacific Spinal and Bulbar Muscular Atrophy Treatment Market Size by Region (2018-2023) & (US$ Million)

    Table 39. Asia-Pacific Spinal and Bulbar Muscular Atrophy Treatment Market Size by Region (2024-2029) & (US$ Million)

    Table 40. Latin America Spinal and Bulbar Muscular Atrophy Treatment Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 41. Latin America Spinal and Bulbar Muscular Atrophy Treatment Market Size by Country (2018-2023) & (US$ Million)

    Table 42. Latin America Spinal and Bulbar Muscular Atrophy Treatment Market Size by Country (2024-2029) & (US$ Million)

    Table 43. Middle East & Africa Spinal and Bulbar Muscular Atrophy Treatment Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 44. Middle East & Africa Spinal and Bulbar Muscular Atrophy Treatment Market Size by Country (2018-2023) & (US$ Million)

    Table 45. Middle East & Africa Spinal and Bulbar Muscular Atrophy Treatment Market Size by Country (2024-2029) & (US$ Million)

    Table 46. AbbVie Company Detail

    Table 47. AbbVie Business Overview

    Table 48. AbbVie Spinal and Bulbar Muscular Atrophy Treatment Product

    Table 49. AbbVie Revenue in Spinal and Bulbar Muscular Atrophy Treatment Business (2018-2023) & (US$ Million)

    Table 50. AbbVie Recent Development

    Table 51. Pfizer Company Detail

    Table 52. Pfizer Business Overview

    Table 53. Pfizer Spinal and Bulbar Muscular Atrophy Treatment Product

    Table 54. Pfizer Revenue in Spinal and Bulbar Muscular Atrophy Treatment Business (2018-2023) & (US$ Million)

    Table 55. Pfizer Recent Development

    Table 56. GlaxoSmithKline Company Detail

    Table 57. GlaxoSmithKline Business Overview

    Table 58. GlaxoSmithKline Spinal and Bulbar Muscular Atrophy Treatment Product

    Table 59. GlaxoSmithKline Revenue in Spinal and Bulbar Muscular Atrophy Treatment Business (2018-2023) & (US$ Million)

    Table 60. GlaxoSmithKline Recent Development

    Table 61. Johnson & Johnson Company Detail

    Table 62. Johnson & Johnson Business Overview

    Table 63. Johnson & Johnson Spinal and Bulbar Muscular Atrophy Treatment Product

    Table 64. Johnson & Johnson Revenue in Spinal and Bulbar Muscular Atrophy Treatment Business (2018-2023) & (US$ Million)

    Table 65. Johnson & Johnson Recent Development

    Table 66. Century Pharmaceuticals Company Detail

    Table 67. Century Pharmaceuticals Business Overview

    Table 68. Century Pharmaceuticals Spinal and Bulbar Muscular Atrophy Treatment Product

    Table 69. Century Pharmaceuticals Revenue in Spinal and Bulbar Muscular Atrophy Treatment Business (2018-2023) & (US$ Million)

    Table 70. Century Pharmaceuticals Recent Development

    Table 71. Astellas Pharma Company Detail

    Table 72. Astellas Pharma Business Overview

    Table 73. Astellas Pharma Spinal and Bulbar Muscular Atrophy Treatment Product

    Table 74. Astellas Pharma Revenue in Spinal and Bulbar Muscular Atrophy Treatment Business (2018-2023) & (US$ Million)

    Table 75. Astellas Pharma Recent Development

    Table 76. Sanofi Company Detail

    Table 77. Sanofi Business Overview

    Table 78. Sanofi Spinal and Bulbar Muscular Atrophy Treatment Product

    Table 79. Sanofi Revenue in Spinal and Bulbar Muscular Atrophy Treatment Business (2018-2023) & (US$ Million)

    Table 80. Sanofi Recent Development

    Table 81. Boehringer Ingelheim International Company Detail

    Table 82. Boehringer Ingelheim International Business Overview

    Table 83. Boehringer Ingelheim International Spinal and Bulbar Muscular Atrophy Treatment Product

    Table 84. Boehringer Ingelheim International Revenue in Spinal and Bulbar Muscular Atrophy Treatment Business (2018-2023) & (US$ Million)

    Table 85. Boehringer Ingelheim International Recent Development

    Table 86. Research Programs/Design for This Report

    Table 87. Key Data Information from Secondary Sources

    Table 88. Key Data Information from Primary Sources

List of Figures

    Figure 1. Global Spinal and Bulbar Muscular Atrophy Treatment Market Size Comparison by Type (2023-2029) & (US$ Million)

    Figure 2. Global Spinal and Bulbar Muscular Atrophy Treatment Market Share by Type: 2022 VS 2029

    Figure 3. 5α-Reductase Inhibitors Features

    Figure 4. Gonadotropin-releasing Hormone Agonists Features

    Figure 5. Global Spinal and Bulbar Muscular Atrophy Treatment Market Size Comparison by Application (2023-2029) & (US$ Million)

    Figure 6. Global Spinal and Bulbar Muscular Atrophy Treatment Market Share by Application: 2022 VS 2029

    Figure 7. Hospitals Case Studies

    Figure 8. Orthopedic Clinics Case Studies

    Figure 9. Ambulatory Surgical Centers Case Studies

    Figure 10. Spinal and Bulbar Muscular Atrophy Treatment Report Years Considered

    Figure 11. Global Spinal and Bulbar Muscular Atrophy Treatment Market Size (US$ Million), Year-over-Year: 2018-2029

    Figure 12. Global Spinal and Bulbar Muscular Atrophy Treatment Market Size, (US$ Million), 2018 VS 2022 VS 2029

    Figure 13. Global Spinal and Bulbar Muscular Atrophy Treatment Market Share by Region: 2022 VS 2029

    Figure 14. Global Spinal and Bulbar Muscular Atrophy Treatment Market Share by Players in 2022

    Figure 15. Global Top Spinal and Bulbar Muscular Atrophy Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Spinal and Bulbar Muscular Atrophy Treatment as of 2022)

    Figure 16. The Top 10 and 5 Players Market Share by Spinal and Bulbar Muscular Atrophy Treatment Revenue in 2022

    Figure 17. North America Spinal and Bulbar Muscular Atrophy Treatment Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 18. North America Spinal and Bulbar Muscular Atrophy Treatment Market Share by Country (2018-2029)

    Figure 19. United States Spinal and Bulbar Muscular Atrophy Treatment Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 20. Canada Spinal and Bulbar Muscular Atrophy Treatment Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 21. Europe Spinal and Bulbar Muscular Atrophy Treatment Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 22. Europe Spinal and Bulbar Muscular Atrophy Treatment Market Share by Country (2018-2029)

    Figure 23. Germany Spinal and Bulbar Muscular Atrophy Treatment Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 24. France Spinal and Bulbar Muscular Atrophy Treatment Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 25. U.K. Spinal and Bulbar Muscular Atrophy Treatment Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 26. Italy Spinal and Bulbar Muscular Atrophy Treatment Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 27. Russia Spinal and Bulbar Muscular Atrophy Treatment Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 28. Nordic Countries Spinal and Bulbar Muscular Atrophy Treatment Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 29. Asia-Pacific Spinal and Bulbar Muscular Atrophy Treatment Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 30. Asia-Pacific Spinal and Bulbar Muscular Atrophy Treatment Market Share by Region (2018-2029)

    Figure 31. China Spinal and Bulbar Muscular Atrophy Treatment Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 32. Japan Spinal and Bulbar Muscular Atrophy Treatment Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 33. South Korea Spinal and Bulbar Muscular Atrophy Treatment Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 34. Southeast Asia Spinal and Bulbar Muscular Atrophy Treatment Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 35. India Spinal and Bulbar Muscular Atrophy Treatment Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 36. Australia Spinal and Bulbar Muscular Atrophy Treatment Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 37. Latin America Spinal and Bulbar Muscular Atrophy Treatment Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 38. Latin America Spinal and Bulbar Muscular Atrophy Treatment Market Share by Country (2018-2029)

    Figure 39. Mexico Spinal and Bulbar Muscular Atrophy Treatment Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 40. Brazil Spinal and Bulbar Muscular Atrophy Treatment Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 41. Middle East & Africa Spinal and Bulbar Muscular Atrophy Treatment Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 42. Middle East & Africa Spinal and Bulbar Muscular Atrophy Treatment Market Share by Country (2018-2029)

    Figure 43. Turkey Spinal and Bulbar Muscular Atrophy Treatment Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 44. Saudi Arabia Spinal and Bulbar Muscular Atrophy Treatment Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 45. AbbVie Revenue Growth Rate in Spinal and Bulbar Muscular Atrophy Treatment Business (2018-2023)

    Figure 46. Pfizer Revenue Growth Rate in Spinal and Bulbar Muscular Atrophy Treatment Business (2018-2023)

    Figure 47. GlaxoSmithKline Revenue Growth Rate in Spinal and Bulbar Muscular Atrophy Treatment Business (2018-2023)

    Figure 48. Johnson & Johnson Revenue Growth Rate in Spinal and Bulbar Muscular Atrophy Treatment Business (2018-2023)

    Figure 49. Century Pharmaceuticals Revenue Growth Rate in Spinal and Bulbar Muscular Atrophy Treatment Business (2018-2023)

    Figure 50. Astellas Pharma Revenue Growth Rate in Spinal and Bulbar Muscular Atrophy Treatment Business (2018-2023)

    Figure 51. Sanofi Revenue Growth Rate in Spinal and Bulbar Muscular Atrophy Treatment Business (2018-2023)

    Figure 52. Boehringer Ingelheim International Revenue Growth Rate in Spinal and Bulbar Muscular Atrophy Treatment Business (2018-2023)

    Figure 53. Bottom-up and Top-down Approaches for This Report

    Figure 54. Data Triangulation

    Figure 55. Key Executives Interviewed